Windward Bio develops antibodies against immunological diseases, including WIN378, an anti-TSLP in phase 2/3 testing in asthma. It has raised USD 165 million in a crossover round led by OrbiMed to advance its clinical programmes.
- Announced on
- Round
- Undisclosed round
- Amount
- USD 165 M
- Location
- Basel, canton of Basel-Stadt
- Sector
- Biotech & life sciences
Investors
- OrbiMed lead
- Novo Holdings
- Blue Owl Healthcare Opportunities
- SR One
- Omega Funds
- RTW Investments
- Qiming Venture Partners
- Quan Capital
- Pivotal bioVenture Partners
- RA Capital Management
- Janus Henderson Investors
- Sanofi Ventures
- Harbour BioMed
Preparing a similar round?
The diagnostic shows you the instruments and investors that fit your stage.
Start the diagnostic